Comments
Ahmedabad-based healthcare player Zydus Cadila has registered 23 per cent rise in the consolidated net profit for the first quarter ended June 2014 at Rs 240 crore against Rs 195 crore shown in the corresponding period last year.
The company has reported consolidated sales of Rs 2,057 crore, up by 25 per cent from Rs 1,646 crore in the same quarter last year.
Sales growth was buoyed by the company’s formulations business in US, which grew by 88 per cent during the quarter. Also, the group had filed 26 additional ANDAs with the USFDA and launched four new products in the US during the quarter.
The group posted a growth of 19 per cent with 12 new product launches in the different Emerging Markets during the quarter. In the domestic formulations market, the company launched 19 new products, including line extensions, of which six products were the first to be launched in India, the company informed in a statement after announcing results.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.